| 主权项 |
1. A compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein:
W is: Q is:
(a) naphthalenyl or isoquinolinyl, each substituted with zero to 3 substituents independently selected from —OH, —CN, halo, —NO2, —C(O)OH, —C(O)O(C1-4 alkyl), —S(O)2(C1-4 alkyl), —S(CH2)1-3C(O)OH, —S(CH2)1-3NH2, C1-4 alkoxy, —OCH(CH3)CH2N(C1-4 alkyl)2, —O(CH2)1-3Rx, —O(CH2)3N(CH3)2, —O(CH2)1-4OH, —O(CH2)1-4O(C1-4 alkyl), —O(CH2)1-4O(phenyl), —N(C1-4 alkyl)2, —C(O)N(C1-4 alkyl)2, —C(O)Rx, and/or —NHC(O)Rx;(b) each substituted with zero to 3 substituents independently selected from halo, C1-4 alkyl, C(O)(C1-4 alkyl), —C(O)Rx, —C(O)(CH2)1-3Rx, —C(O)O(C1-4 alkyl), —(CH2)1-3Rx, —C(O)(CH2)1-3S(phenyl), —(CH2)1-3S(phenyl), C2-4 alkenyl, and/or morpholinyl; or
(c) C1-6 alkyl or —(CH2)1-3(trimethylsilyl), provided that W is each Rx is independently C3-6 cycloalkyl, phenyl, chlorophenyl, difluorophenyl, dichlorophenyl, benzoic acid, methyl benzoate, methylsulfonylphenyl, pyridinyl, chloropyridinyl, furanyl, pyrrolidinyl, piperidinyl, morpholinyl, (morpholinoethoxy)pyridinyl, N-methylpyrrolidinyl, N-methylpiperazinyl, N-methyl-1H-imidazolyl, 1-methyl-1H-indolyl, or N-(2-hydroxyethyl)piperazinyl; G is:
(a) —N(C1-4 alkyl)2; or(b) a bicyclic heterocyclyl selected from: wherein said bicyclic heterocyclyl is substituted with zero to 3 substituents independently selected from: halo, C1-4 alkyl, C1-4 fluoroalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, —(CH2)0-3C(O)OH, —(CH2)1-3NH2, —(CH2)1-3N3, —(CH2)1-3N(CH3)(C1-4 hydroxyalkyl), —(CH2)1-3N(CH3)((CH2)1-3OCH3), —(CH2)1-3O(CH2)1-3N(C1-4 alkyl)2, —(CH2)1-3O(CH2)1-3OH, —(CH2)1-3O(CH2)1-3(C1-4 alkyl), —(CH2)1-3O(CH2)1-3O(phenyl), —(CH2)1-3O(CH2)1-3CH3, —(CH2)1-3Rx, —(CH2)0-3N(CH3)2, —N(CH3)((CH2)1-3O(C1-4 alkyl), R1a is H, halo, C1-6 alkyl, —CF3, C1-4 hydroxyalkyl, —(CH2)1-3O(C1-4 alkyl), —(CH2)1-3O(C1-4 hydroxyalkyl), —(CH2)0-3C(O)OH, —(CH2)0-3N(C1-4 alkyl)2, —(CH2)0-3C(O)NH(C1-4 alkyl), —(CH2)1-3Rx, —(CH2)0-3OC(O)NH2, —(CH2)0-3C(O)NHS(O)2(C3-6 cycloalkyl), —(CH2)1-3OC(O)Rx, or —(CH2)0-3OC(O)NH(CH2)1-3Rx; R1b is H, C1-6 alkyl, —CF3, C1-4 hydroxyalkyl, —(CH2)1-3O(C1-4 alkyl), —(CH2)1-3O(C1-4 hydroxyalkyl), —(CH2)0-3C(O)OH, —(CH2)0-3N(C1-4 alkyl)2, —(CH2)0-3C(O)NH(C1-4 alkyl), —(CH2)1-3Rx, —(CH2)0-3OC(O)NH2, —(CH2)0-3C(O)NHS(O)2(C3-6 cycloalkyl), —(CH2)1-3OC(O)Rx, or —(CH2)0-3 OC(O)NH(CH2)1-3Rx; R2 is:
(a) H, Cl, Br, C1-3 hydroxyalkyl, —(CH2)0-3C(O)OH, or —(CH2)0-3N(CH3)2; or(b) phenyl substituted with zero to 2 substituents independently selected from C1-4 alkyl, —(CH2)0-3OH, —O(CH3)0-3CH3, —O(CH2)1-3OH, —O(CH2)1-2CH(OH)(CH2)1-2OH, —O(C2-4 alkenyl), —ORx, —C(O)O(C1-4 alkyl), and/or phenyl; R2a is:
(a) H, C1-3 hydroxyalkyl, —(CH2)0-3C(O)OH, or —(CH2)0-3N(CH3)2; or(b) phenyl substituted with zero to 2 substituents independently selected from C1-4 alkyl, —(CH2)0-3OH, —O(CH3)0-3CH3, —O(CH2)1-3OH, —O(CH2)1-2CH(OH)(CH2)1-2OH, —O(C2-4 alkenyl), —ORx, —C(O)O(C1-4 alkyl), and/or phenyl; one of R2b and R2c is H and the other of R2b and R2c is R2; R3 is —(CH2)1-3OH, —C(O)OH, —C(O)O(C1-4 alkyl), —C(O)NRaRb, or —NRaRb; Ra is H, C1-6 alkyl, or C1-4 fluoroalkyl; and Rb is
(a) C1-6 alkyl, C1-4 fluoroalkyl, —(CH2)1-3C(O)OH, —(CH2)1-3C(O)O(C1-4 alkyl), —(CH2)1-3(C3-6 cycloalkyl), —CH2(naphthalenyl), —(CH2)1-3C(O)NHCH(C1-4 hydroxyalkyl)2, —(CH2)1-3C(O)NHCH(C1-4 hydroxyalkyl)3, or —(CH2)1-3C(O)NH(CH2)1-3Rx;(b) —(CH2)0-2(phenyl) wherein said phenyl is substituted with zero to 2 substituents independently selected from Cl, I, C1-4 alkyl, C1-4 alkoxy, —(CH2)0-3C(O)OH, —C(O)O(C1-4alkyl), —(CH2)1-3C(O)O(C1-4alkyl), phenyl, halophenyl, halophenoxy, phenyl acetic acid, and/or —(CH2)1-3C(O)Rx; or(c) or Ra and Rb, together with the nitrogen atom to which they are attached, form a pyrrolidinyl ring substituted with zero to 1 substituent selected from C1-4alkyl or —(CH2)1-3(phenyl). |
